Monitoring treatment: quantifying patient-specific efficacy

This unit will focus on the full quantitative data generated in AMYPAD to go beyond the analyses planned in the diagnostic and prognostic studies that both focus on global amyloid status as a dichotomous measure. This group works closely with EPAD, which focuses on risk prediction modelling and development of adaptive trial methodology for intervention studies.

The ultimate goal is to establish predictors of decline by using quantitative baseline and longitudinal PET measurements and determine how this can be best used to plan and monitor treatment.